Drummond alerts National Security Council to exploitation of FDA approved drugs by Chinese businesses
OKLAHOMA CITY (Sept. 21, 2026) – Attorney General Gentner Drummond is alerting Secretary of State Marco Rubio to a national security risk to the pharmaceutical supply chain that is being exploited by Chinese businesses.
Drummond and 19 other state attorneys general sent a letter last week to Secretary Rubio identifying national security risks from dangerous pharmaceutical ingredients used in popular compounded GLP-1 drugs, including semaglutide, tirzepatide and retatrutide. In one instance, a business in China exploiting gaps in oversight had direct ties to entities who manufacture fentanyl.
“Chinese businesses have found and exploited a gap in the system that gives them a direct line to patients in the U.S. who use popular injectable prescription drugs,” Drummond said. “This exploitation not only poses risks to the health and safety of consumers, but it constitutes a national security risk.”
Drummond and the coalition are urging Secretary Rubio and the National Security Council to establish greater oversight of the Green List program or halt the potentially deadly ingredients from entering the country disguised as safe prescription medication.
In September 2025, the Food and Drug Administration (FDA) authorized the creation of a Green List of suppliers, which has effectively given Chinese suppliers the ability to ship unapproved, knock-off products to the United States without detention or inspection. As the letter states, despite efforts to verify the true source, chain of command and downstream use of the ingredients in real time, the Green List has become a laundering channel.
Harbin Jixianglong Biotech Co., Ltg (Harbin), a Chinese company, was found to have purchased knock-off semaglutide from a non-Green List facility that was not registered with the FDA. Since Harbin was on the Green List, it was only after an on-site inspection that it was discovered that Harbin had repackaged and relabeled the non-Green List products under Harbin’s name, changed the manufacturing and retest dates, and distributed them to the United States.
Other states joining the letter include Alabama, Arkansas, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Mississippi, Missouri, Montana, Nebraska, North Dakota, Ohio, South Carolina, Tennessee, Utah and West Virginia.
